Terms: = Endocrine gland cancer AND CDK12, KIAA0904, CRKRS, 51755, ENSG00000167258, CRK7, CRKR, Q9NYV4
37 results:
1. Ovarian high-grade serous carcinoma with transitional-like (SET) morphology: a homologous recombination-deficient tumor.
D'Angelo E; Espinosa I; Felicioni L; Buttitta F; Prat J
Hum Pathol; 2023 Nov; 141():15-21. PubMed ID: 37673346
[TBL] [Abstract] [Full Text] [Related]
2. Dual inhibition of cdk12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids.
Cesari E; Ciucci A; Pieraccioli M; Caggiano C; Nero C; Bonvissuto D; Sillano F; Buttarelli M; Piermattei A; Loverro M; Camarda F; Greco V; De Bonis M; Minucci A; Gallo D; Urbani A; Vizzielli G; Scambia G; Sette C
J Exp Clin Cancer Res; 2023 May; 42(1):126. PubMed ID: 37202753
[TBL] [Abstract] [Full Text] [Related]
3. Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer.
Peng H; Li L; Zuo C; Chen MY; Zhang X; Myers NB; Hogg GD; DeNardo DG; Goedegebuure SP; Hawkins WG; Gillanders WE
Front Immunol; 2022; 13():1039226. PubMed ID: 36569934
[TBL] [Abstract] [Full Text] [Related]
4. Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer.
Coelho R; Tozzi A; Disler M; Lombardo F; Fedier A; López MN; Freuler F; Jacob F; Heinzelmann-Schwarz V
Cell Death Dis; 2022 Oct; 13(10):909. PubMed ID: 36307400
[TBL] [Abstract] [Full Text] [Related]
5. Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer.
Laha D; Grant RRC; Mishra P; Boufraqech M; Shen M; Zhang YQ; Hall MD; Quezado M; De Melo MS; Del Rivero J; Zeiger M; Nilubol N
J Exp Clin Cancer Res; 2022 Sep; 41(1):282. PubMed ID: 36151566
[TBL] [Abstract] [Full Text] [Related]
6. Current progress and novel strategies that target cdk12 for drug discovery.
Lei P; Zhang J; Liao P; Ren C; Wang J; Wang Y
Eur J Med Chem; 2022 Oct; 240():114603. PubMed ID: 35868123
[TBL] [Abstract] [Full Text] [Related]
7. Dual Inhibition of cdk12/CDK13 Targets Both Tumor and Immune Cells in Ovarian cancer.
Cheng L; Zhou S; Zhou S; Shi K; Cheng Y; Cai MC; Ye K; Lin L; Zhang Z; Jia C; Xiang H; Zang J; Zhang M; Yin X; Li Y; Di W; Zhuang G; Tan L
Cancer Res; 2022 Oct; 82(19):3588-3602. PubMed ID: 35857807
[TBL] [Abstract] [Full Text] [Related]
8. A Phase II Trial to Evaluate the Efficacy of Bortezomib and Liposomal Doxorubicin in Patients With BRCA Wild-type Platinum-resistant Recurrent Ovarian cancer (KGOG 3044/EBLIN).
Lee YJ; Seol A; Lee M; Kim JW; Kim HS; Kim K; Suh DH; Kim S; Kim SW; Lee JY
In Vivo; 2022; 36(4):1949-1958. PubMed ID: 35738633
[TBL] [Abstract] [Full Text] [Related]
9. Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort.
Leibowitz BD; Dougherty BV; Bell JSK; Kapilivsky J; Michuda J; Sedgewick AJ; Munson WA; Chandra TA; Dry JR; Beaubier N; Igartua C; Taxter T
BMC Cancer; 2022 May; 22(1):587. PubMed ID: 35643464
[TBL] [Abstract] [Full Text] [Related]
10. The Molecular Landscape of Pancreatobiliary cancers for Novel Targeted Therapies From Real-World Genomic Profiling.
Umemoto K; Yamamoto H; Oikawa R; Takeda H; Doi A; Horie Y; Arai H; Ogura T; Mizukami T; Izawa N; Moore JA; Sokol ES; Sunakawa Y
J Natl Cancer Inst; 2022 Sep; 114(9):1279-1286. PubMed ID: 35583261
[TBL] [Abstract] [Full Text] [Related]
11. SOX17 and PAX8 constitute an actionable lineage-survival transcriptional complex in ovarian cancer.
Lin L; Shi K; Zhou S; Cai MC; Zhang C; Sun Y; Zang J; Cheng L; Ye K; Ma P; Shen P; Zhang M; Cheng Y; Qi C; Li Y; Yin X; Zheng Y; Tan L; Zhuang G; Zang R
Oncogene; 2022 Mar; 41(12):1767-1779. PubMed ID: 35124696
[TBL] [Abstract] [Full Text] [Related]
12. Control of Expression of Key Cell Cycle Enzymes Drives Cell Line-Specific Functions of CDK7 in Human PDAC Cells.
Kolloch L; Kreinest T; Meisterernst M; Oeckinghaus A
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054996
[TBL] [Abstract] [Full Text] [Related]
13. Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
Swisher EM; Kristeleit RS; Oza AM; Tinker AV; Ray-Coquard I; Oaknin A; Coleman RL; Burris HA; Aghajanian C; O'Malley DM; Leary A; Welch S; Provencher D; Shapiro GI; Chen LM; Shapira-Frommer R; Kaufmann SH; Goble S; Maloney L; Kwan T; Lin KK; McNeish IA
Gynecol Oncol; 2021 Dec; 163(3):490-497. PubMed ID: 34602290
[TBL] [Abstract] [Full Text] [Related]
14. Kinome capture sequencing of high-grade serous ovarian carcinoma reveals novel mutations in the JAK3 gene.
Mittempergher L; Piskorz AM; Bosma AJ; Michaut M; Wisman GBA; Kluin RJC; Nieuwland M; Brugman W; van der Ven KJW; Marass F; Morris J; Rosenfeld N; Jimenez-Linan M; de Jong S; van der Zee AGJ; Brenton JD; Bernards R
PLoS One; 2020; 15(7):e0235766. PubMed ID: 32639993
[TBL] [Abstract] [Full Text] [Related]
15. Lack of evidence for cdk12 as an ovarian cancer predisposing gene.
Eeckhoutte A; Saint-Ghislain M; Reverdy M; Raynal V; Baulande S; Bataillon G; Golmard L; Stoppa-Lyonnet D; Popova T; Houdayer C; Manié E; Stern MH
Fam Cancer; 2020 Jul; 19(3):203-209. PubMed ID: 32172432
[TBL] [Abstract] [Full Text] [Related]
16. A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic cancer.
Zhong J; Jermusyk A; Wu L; Hoskins JW; Collins I; Mocci E; Zhang M; Song L; Chung CC; Zhang T; Xiao W; Albanes D; Andreotti G; Arslan AA; Babic A; Bamlet WR; Beane-Freeman L; Berndt S; Borgida A; Bracci PM; Brais L; Brennan P; Bueno-de-Mesquita B; Buring J; Canzian F; Childs EJ; Cotterchio M; Du M; Duell EJ; Fuchs C; Gallinger S; Gaziano JM; Giles GG; Giovannucci E; Goggins M; Goodman GE; Goodman PJ; Haiman C; Hartge P; Hasan M; Helzlsouer KJ; Holly EA; Klein EA; Kogevinas M; Kurtz RJ; LeMarchand L; Malats N; Männistö S; Milne R; Neale RE; Ng K; Obazee O; Oberg AL; Orlow I; Patel AV; Peters U; Porta M; Rothman N; Scelo G; Sesso HD; Severi G; Sieri S; Silverman D; Sund M; Tjønneland A; Thornquist MD; Tobias GS; Trichopoulou A; Van Den Eeden SK; Visvanathan K; Wactawski-Wende J; Wentzensen N; White E; Yu H; Yuan C; Zeleniuch-Jacquotte A; Hoover R; Brown K; Kooperberg C; Risch HA; Jacobs EJ; Li D; Yu K; Shu XO; Chanock SJ; Wolpin BM; Stolzenberg-Solomon RZ; Chatterjee N; Klein AP; Smith JP; Kraft P; Shi J; Petersen GM; Zheng W; Amundadottir LT
J Natl Cancer Inst; 2020 Oct; 112(10):1003-1012. PubMed ID: 31917448
[TBL] [Abstract] [Full Text] [Related]
17. BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian cancer Cells to Mitochondrial Metabolic Targeting Agents.
Kanakkanthara A; Kurmi K; Ekstrom TL; Hou X; Purfeerst ER; Heinzen EP; Correia C; Huntoon CJ; O'Brien D; Wahner Hendrickson AE; Dowdy SC; Li H; Oberg AL; Hitosugi T; Kaufmann SH; Weroha SJ; Karnitz LM
Cancer Res; 2019 Dec; 79(23):5920-5929. PubMed ID: 31619387
[TBL] [Abstract] [Full Text] [Related]
18. Targeting cdk12-mediated transcription regulation in anaplastic thyroid carcinoma.
Geng M; Yang Y; Cao X; Dang L; Zhang T; Zhang L
Biochem Biophys Res Commun; 2019 Dec; 520(3):544-550. PubMed ID: 31615655
[TBL] [Abstract] [Full Text] [Related]
19. Human Testis Phosphoproteome Reveals Kinases as Potential Targets in Spermatogenesis and Testicular cancer.
Castillo J; Knol JC; Korver CM; Piersma SR; Pham TV; de Goeij-de Haas RR; van Pelt AMM; Jimenez CR; Jansen BJH
Mol Cell Proteomics; 2019 Mar; 18(Suppl 1):S132-S144. PubMed ID: 30683686
[TBL] [Abstract] [Full Text] [Related]
20. Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and cdk12/13.
Zeng M; Kwiatkowski NP; Zhang T; Nabet B; Xu M; Liang Y; Quan C; Wang J; Hao M; Palakurthi S; Zhou S; Zeng Q; Kirschmeier PT; Meghani K; Leggett AL; Qi J; Shapiro GI; Liu JF; Matulonis UA; Lin CY; Konstantinopoulos PA; Gray NS
Elife; 2018 Nov; 7():. PubMed ID: 30422115
[TBL] [Abstract] [Full Text] [Related]
[Next]
